Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis

Tong,Zhufeng; Wang,Zhen; Jiang,Jinghan; Fu,Wenqi; Hu,Siying

doi:10.3892/ol.2025.14954

Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis

Authors:
- Zhufeng Tong
- Zhen Wang
- Jinghan Jiang
- Wenqi Fu
- Siying Hu
View Affiliations

Affiliations: Department of General Practice, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241000, P.R. China
Published online on: March 4, 2025 https://doi.org/10.3892/ol.2025.14954
Article Number: 207
Copyright: © Tong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to elucidate the mechanism by which glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer. Initially, A549 cells were treated with different concentrations of glycyrrhizin (0.25‑8 mM) or cisplatin (10‑160 µM) for 48 h to investigate the effect of glycyrrhizin combined with cisplatin on A549 cells in vitro. Subsequently, A549 cells were divided into control (untreated), CP (20 µM cisplatin), GL (2 mM glycyrrhizin) and CP + GL (20 µM cisplatin + 2 mM glycyrrhizin) groups to elucidate the underlying mechanism of glycyrrhizin. After 48 h incubation, the viability and colony‑forming ability of the cells were assessed using MTT and colony formation assays. Apoptosis levels and cell cycle progression were analyzed using flow cytometry and western blotting was used to evaluate apoptosis‑ and cell cycle‑related proteins. Additionally, comet assays and western blotting were used to evaluate DNA damage and relevant proteins. The results demonstrated both glycyrrhizin and cisplatin individually reduced A549 cell viability in a concentration‑dependent manner. Cisplatin demonstrated a lower half‑maximal inhibitory concentration (IC₅₀) at higher glycyrrhizin concentrations, with an IC₅₀ value of ~35 µM with 2 mM glycyrrhizin. Furthermore, the combined treatment of glycyrrhizin and cisplatin synergistically reduced cell colony‑forming ability, induced apoptosis and arrested the cell cycle at the G₂ phase, showing greater efficacy when compared with either treatment individually. In addition, western blotting analysis demonstrated that, in comparison with treatment with cisplatin or glycyrrhizin alone, the combined treatment markedly increased the protein expression levels of B‑cell lymphoma 2‑associated X protein, cleaved‑caspase‑3/caspase‑3, γH2AX, phosphorylated‑checkpoint kinase 1 and phosphorylated‑p53/p53, while notably reducing the protein levels of B‑cell lymphoma 2, cyclin D1, cyclin‑dependent kinase 2 and cyclin‑dependent kinase 4. The findings of the present study indicate that glycyrrhizin enhances the antitumor efficacy of cisplatin in non‑small cell lung cancer cells by modulating DNA damage and apoptosis.

View Figures

View References

1	Chen P, Liu Y, Wen Y and Zhou C: Non-small cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022. View Article : Google Scholar : PubMed/NCBI
2	Duma N, Santana-Davila R and Molina JR: Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
3	Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W and Xia Y: Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond). 44:23–46. 2024. View Article : Google Scholar : PubMed/NCBI
4	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
5	Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G and Reck M: Non-small-cell lung cancer. Nat Rev Dis Primers. 10:712024. View Article : Google Scholar : PubMed/NCBI
6	Xu J and Gewirtz DA: Is autophagy always a barrier to cisplatin therapy? Biomolecules. 12:4632022. View Article : Google Scholar : PubMed/NCBI
7	Dasari S, Njiki S, Mbemi A, Yedjou CG and Tchounwou PB: Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int J Mol Sci. 23:15322022. View Article : Google Scholar : PubMed/NCBI
8	Qi L, Luo Q, Zhang Y, Jia F, Zhao Y and Wang F: Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 32:1469–1486. 2019. View Article : Google Scholar : PubMed/NCBI
9	Sun C, Gao W, Liu J, Cheng H and Hao J: FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res. 21:2102020. View Article : Google Scholar : PubMed/NCBI
10	Gui YR, Zhang Y, Wang XQ, Fan BJ, Li JL, Zhang LX, Fan F, Cao KD, Zhang XG and Hou W: Treatment of lung cancer with orally administered Chinese herbal medicine: An evidence map between 1970–2020. Chin J Integr Med. 28:930–938. 2022. View Article : Google Scholar : PubMed/NCBI
11	Singh M, Sharma P, Singh PK, Singh TG and Saini B: Medicinal potential of heterocyclic compounds from diverse natural sources for the management of cancer. Mini Rev Med Chem. 20:942–957. 2020. View Article : Google Scholar : PubMed/NCBI
12	Masraksa W, Tanasawet S, Hutamekalin P, Wongtawatchai T and Sukketsiri W: Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway. Nutr Res Pract. 14:127–133. 2020. View Article : Google Scholar : PubMed/NCBI
13	Kalaiarasi A, Anusha C, Sankar R, Rajasekaran S, John Marshal J, Muthusamy K and Ravikumar V: Plant isoquinoline alkaloid berberine exhibits chromatin remodeling by modulation of histone deacetylase to induce growth arrest and apoptosis in the A549 cell line. J Agric Food Chem. 64:9542–9550. 2016. View Article : Google Scholar : PubMed/NCBI
14	Deng QD, Lei XP, Zhong YH, Chen MS, Ke YY, Li Z, Chen J, Huang LJ, Zhang Y, Liang L, et al: Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition. Acta Pharmacol Sin. 42:1486–1497. 2021. View Article : Google Scholar : PubMed/NCBI
15	Wei Z, Chen J, Zuo F, Guo J, Sun X, Liu D and Liu C: Traditional Chinese medicine has great potential as candidate drugs for lung cancer: A review. J Ethnopharmacol. 300:1157482023. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Yan S, Li Y, Zhang J, Luo Y, Li P, Yang Y, Li Y, Huang Y and Wang E: Inhibin βA is an independent prognostic factor that promotes invasion via Hippo signaling in non-small cell lung cancer. Mol Med Rep. 24:7892021. View Article : Google Scholar : PubMed/NCBI
17	Zhang J, Li C, Zhang L, Heng Y, Xu T, Zhang Y, Chen X, Hoffman RM and Jia L: Andrographolide induces noxa-dependent apoptosis by transactivating ATF4 in human lung adenocarcinoma cells. Front Pharmacol. 12:6805892021. View Article : Google Scholar : PubMed/NCBI
18	Wang Q, Jiao L, Wang S, Chen P, Bi L, Zhou D, Yao J, Li J, Wang L, Chen Z, et al: Adjuvant chemotherapy with Chinese herbal medicine formulas versus placebo in patients with lung adenocarcinoma after radical surgery: A multicenter, randomized, double-blind, placebo-controlled trial. Biol Proced Online. 22:52020. View Article : Google Scholar : PubMed/NCBI
19	Chrzanowski J, Chrzanowska A and Graboń W: Glycyrrhizin: An old weapon against a novel coronavirus. Phytother Res. 35:629–636. 2021. View Article : Google Scholar : PubMed/NCBI
20	Bravo V, Serrano M, Duque A, Ferragud J and Coronado PJ: Glycyrrhizinic acid as an antiviral and anticancer agent in the treatment of human papillomavirus. J Pers Med. 13:16392023. View Article : Google Scholar : PubMed/NCBI
21	Han Y, Sheng W, Liu X, Liu H, Jia X, Li H, Wang C, Wang B, Hu T and Ma Y: Glycyrrhizin ameliorates colorectal cancer progression by regulating NHEJ pathway through inhibiting HMGB1-induced DNA damage response. Sci Rep. 14:249482024. View Article : Google Scholar : PubMed/NCBI
22	Jain R, Hussein MA, Pierce S, Martens C, Shahagadkar P and Munirathinam G: Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights. Pharmacol Res. 178:1061382022. View Article : Google Scholar : PubMed/NCBI
23	Zhang Y, Sheng Z, Xiao J, Li Y, Huang J, Jia J, Zeng X and Li L: Advances in the roles of glycyrrhizic acid in cancer therapy. Front Pharmacol. 14:12651722023. View Article : Google Scholar : PubMed/NCBI
24	Wang H, Ge X, Qu H, Wang N, Zhou J, Xu W, Xie J, Zhou Y, Shi L, Qin Z, et al: Glycyrrhizic acid inhibits proliferation of gastric cancer cells by inducing cell cycle arrest and apoptosis. Cancer Manag Res. 12:2853–2861. 2020. View Article : Google Scholar : PubMed/NCBI
25	Huang RY, Chu YL, Jiang ZB, Chen XM, Zhang X and Zeng X: Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase. Cell Physiol Biochem. 33:375–388. 2014. View Article : Google Scholar : PubMed/NCBI
26	Deng QP, Wang MJ, Zeng X, Chen GG and Huang RY: Effects of glycyrrhizin in a mouse model of lung adenocarcinoma. Cell Physiol Biochem. 41:1383–1392. 2017. View Article : Google Scholar : PubMed/NCBI
27	Huan C, Xu Y, Zhang W, Guo T, Pan H and Gao S: Research progress on the antiviral activity of glycyrrhizin and its derivatives in liquorice. Front Pharmacol. 12:6806742021. View Article : Google Scholar : PubMed/NCBI
28	Wakamatsu T, Nakahashi Y, Hachimine D, Seki T and Okazaki K: The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 31:1465–1472. 2007.PubMed/NCBI
29	Tan JY, Zhao F, Deng SX, Zhu HC, Gong Y and Wang W: Glycyrrhizin affects monocyte migration and apoptosis by blocking HMGB1 signaling. Mol Med Rep. 17:5970–5975. 2018.PubMed/NCBI
30	Ahmad A, Tiwari RK, Saeed M, Ahmad I and Ansari IA: Glycyrrhizin mediates downregulation of notch pathway resulting in initiation of apoptosis and disruption in the cell cycle progression in cervical cancer cells. Nutr Cancer. 74:622–639. 2022. View Article : Google Scholar : PubMed/NCBI
31	Thirugnanam S, Xu L, Ramaswamy K and Gnanasekar M: Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP. Oncol Rep. 20:1387–1392. 2008.PubMed/NCBI
32	Sun Y, Liu Y, Ma X and Hu H: The influence of cell cycle regulation on chemotherapy. Int J Mol Sci. 22:69232021. View Article : Google Scholar : PubMed/NCBI
33	Carneiro BA and El-Deiry WS: Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 17:395–417. 2020. View Article : Google Scholar : PubMed/NCBI
34	Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of print). View Article : Google Scholar
35	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: NCCN guidelines insights: Non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021. View Article : Google Scholar : PubMed/NCBI
36	Yan H, Jiang M, Yang F, Tang X, Lin M, Zhou C, Tan Y and Liu D: Ajuforrestin A, an abietane diterpenoid from Ajuga ovalifolia var. calanthe, induces A549 cell apoptosis by targeting SHP2. Molecules. 27:54692022. View Article : Google Scholar : PubMed/NCBI
37	Roohbakhsh A, Iranshahy M and Iranshahi M: Glycyrrhetinic acid and its derivatives: Anti-cancer and cancer chemopreventive properties, mechanisms of action and structure-cytotoxic activity relationship. Curr Med Chem. 23:498–517. 2016. View Article : Google Scholar : PubMed/NCBI
38	Bi YY, Chen Q, Yang MY, Xing L and Jiang HL: Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer. Nat Commun. 15:27592024. View Article : Google Scholar : PubMed/NCBI
39	Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, Mo Q, Zhao X, Fan Q, Deng F, et al: Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 68:1009382023. View Article : Google Scholar : PubMed/NCBI
40	Su X, Wu L, Hu M, Dong W, Xu M and Zhang P: Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed Pharmacother. 95:670–678. 2017. View Article : Google Scholar : PubMed/NCBI
41	Chen L, Yang J, Davey AK, Chen YX, Wang JP and Liu XQ: Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism. Xenobiotica. 39:955–963. 2009. View Article : Google Scholar : PubMed/NCBI
42	Romani AMP: Cisplatin in cancer treatment. Biochem Pharmacol. 206:1153232022. View Article : Google Scholar : PubMed/NCBI
43	Tsai JJ, Pan PJ, Hsu FT, Chung JG and Chiang IT: Glycyrrhizic acid modulates apoptosis through extrinsic/intrinsic pathways and inhibits protein kinase B- and extracellular signal-regulated kinase-mediated metastatic potential in hepatocellular carcinoma in vitro and in vivo. Am J Chin Med. 48:223–244. 2020. View Article : Google Scholar : PubMed/NCBI
44	Cao R, Li Y, Hu X, Qiu Y, Li S, Xie Y, Xu C, Lu C, Chen G and Yang J: Glycyrrhizic acid improves tacrolimus-induced renal injury by regulating autophagy. FASEB J. 37:e227492023. View Article : Google Scholar : PubMed/NCBI
45	Wang Y, Wang L, Luo R, Sun Y, Zou M, Wang T, Guo Q and Peng X: Glycyrrhizic acid against mycoplasma gallisepticum-induced inflammation and apoptosis through suppressing the MAPK pathway in chickens. J Agric Food Chem. 70:1996–2009. 2022. View Article : Google Scholar : PubMed/NCBI
46	Liang B, Guo XL, Jin J, Ma YC and Feng ZQ: Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury. World J Gastroenterol. 21:5271–5280. 2015. View Article : Google Scholar : PubMed/NCBI
47	Azzahra SNA, Hanif N and Hermawan A: MDM2 is a potential target gene of glycyrrhizic acid for circumventing breast cancer resistance to tamoxifen: Integrative bioinformatics analysis. Asian Pac J Cancer Prev. 23:2341–2350. 2022. View Article : Google Scholar : PubMed/NCBI
48	Bentz GL, Lowrey AJ, Horne DC, Nguyen V, Satterfield AR, Ross TD, Harrod AE, Uchakina ON and McKallip RJ: Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency. PLoS One. 14:e02175782019. View Article : Google Scholar : PubMed/NCBI
49	Slovin S, Carissimo A, Panariello F, Grimaldi A, Bouché V, Gambardella G and Cacchiarelli D: Single-cell RNA sequencing analysis: A step-by-step overview. Methods Mol Biol. 2284:343–365. 2021. View Article : Google Scholar : PubMed/NCBI
50	Wei C and Fu Q: Cell death mediated by nanotechnology via the cuproptosis pathway: A novel horizon for cancer therapy. View. 4:202300012023. View Article : Google Scholar
51	Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S and Yu L: The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 11:3432020. View Article : Google Scholar : PubMed/NCBI
52	Yang L, Liu YN, Gu Y and Guo Q: Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatin via inhibiting PI3K/AKT/mTOR and MAPK signaling. World J Gastrointest Oncol. 15:1739–1755. 2023. View Article : Google Scholar : PubMed/NCBI
53	Zhang J, Zhou Q, Xie K, Cheng L, Peng S, Xie R, Liu L, Zhang Y, Dong W, Han J, et al: Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J Exp Clin Cancer Res. 40:2032021. View Article : Google Scholar : PubMed/NCBI
54	Yang Y, Yang Z, Zhang R, Jia C, Mao R, Mahati S, Zhang Y, Wu G, Sun YN, Jia XY, et al: MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway. Biosci Rep. 41:BSR201920072021. View Article : Google Scholar : PubMed/NCBI
55	Li H, Wen X, Ren Y, Fan Z, Zhang J, He G and Fu L: Targeting PI3K family with small-molecule inhibitors in cancer therapy: Current clinical status and future directions. Mol Cancer. 23:1642024. View Article : Google Scholar : PubMed/NCBI
56	Omidi F, Shahbazi S, Reiisi S, Azhdari S and Karimzadeh MR: Glycyrrhizic acid enhances the anticancer activity of cisplatin in the human ovarian cancer cell line. Toxicol In Vitro. 93:1056872023. View Article : Google Scholar : PubMed/NCBI
57	Chueh FS, Hsiao YT, Chang SJ, Wu PP, Yang JS, Lin JJ, Chung JG and Lai TY: Glycyrrhizic acid induces apoptosis in WEHI-3 mouse leukemia cells through the caspase- and mitochondria-dependent pathways. Oncol Rep. 28:2069–2076. 2012. View Article : Google Scholar : PubMed/NCBI